|Results 1 - 10 of 41||Page 1 of 5|
|Results per-page: 10 | 20 | 50 | 100|
Relevance: 100% Posted on: 26th February 2015
The Dementia Consortium will provide funding, resources and expertise to both increase the number of, and capitalise upon, new drug targets emerging from across the academic sector that hold promise of bringing patient benefit.
Relevance: 100% Posted on: 20th February 2015
The Dementia Consortium aims to expedite the development of new drugs for dementia by supporting research into novel targets for neurodegeneration. The progression of each application is assessed by the Dementia Consortium partners and by a panel of drug discovery experts associated with the MRCT Centre for Therapeutics Discovery. MRCT…
Relevance: 100% Posted on: 10th December 2013
New Consortium unites charity, academic and private sectors in search for new treatments
Relevance: 100% Posted on: 19th June 2015
Funding worth nearly half a million pounds will unite academics at the University of Southampton with drug discovery experts at the medical research charity MRC Technology, to target the immune system in the hunt for new treatments for Alzheimer's disease. The work is the first to be funded by the…
Relevance: 100% Posted on: 14th September 2015
The Dementia Consortium, a unique charity-private partnership between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai and Lilly, has invested £305,000 in a new project to identify drugs for frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). A team at the International Centre for Genetic Engineering and Biotechnology…
Relevance: 100% Posted on: 1st March 2016
New dementia drug discovery efforts get underway this month at the University of South Florida, thanks to £875,000 funding from the Dementia Consortium. The US team of academics will work with drug development experts at UK-based MRC Technology, to target the immune system in a bid to halt nerve cell…
Relevance: 100% Posted on: 8th March 2016
The Dementia Consortium has welcomed MSD (Merck & Co., Inc., Kenilworth, USA) as a new partner in their global venture to accelerate drug discovery for neurodegenerative disease. MSD is the latest pharmaceutical company to join the Dementia Consortium – a £4.5 million charity-industry partnership between Alzheimer’s Research UK, MRC Technology…
Relevance: 100% Posted on: 9th November 2017
This unique initiative unites charity, academic and private sectors in the search for new dementia treatments.
Relevance: 100% Posted on: 17th November 2017
The Dementia Consortium provides funding, expertise and resources for promising dementia research.
Relevance: 100% Posted on: 17th August 2018
Find out more about how the Dementia Consortium can support you